Board of Directors

Our Board provides oversight to ensure that the highest Corporate Governance standards are maintained, applies internal financial controls and approves the Company’s policy and strategy.

Annalisa-Jenkins.png

Dr. Annalisa Jenkins, MBBS, FRCP

Executive Chair

DHS photo.jpeg

Dr. David Horn Solomon

Chief Executive Officer

DavidEllam_160sq_circle.png

David Ellam

Chief Financial Officer

AlistairGrey_160sq_circle.png

Alistair Gray

Non-Executive Director

Photo DLemus.jpg

Dave Lemus

Non-Executive Director

StephenParker_160sq_circle.png

Dr. Stephen Parker

Non-Executive Director

AndyRichards_160sq_circle.png

Dr. Andy Richards CBE

Non-Executive Director

Dr. Annalisa Jenkins, MBBS, FRCP

Executive Chair

Dr. Jenkins is a biopharma thought leader with 25 years of industry experience. Until November 2017, she was President and Chief Executive Officer at leading gene therapy company, Dimension Therapeutics. Prior to joining Dimension in September 2014, Annalisa served as head of global research and development at Merck Serono Pharmaceuticals from 2013 to 2014, where she also served as executive vice president global development and medical from 2011 to 2013. Prior to this, Dr. Jenkins held several leadership roles at Bristol Myers-Squibb from 1997 to 2011, most recently serving as senior vice president and head of global medical affairs. Earlier in her career, Dr. Jenkins was a medical officer in the British Royal Navy during the Gulf Conflict, achieving the rank of surgeon lieutenant commander.

Annalisa-Jenkins.png

Appointed

October 2017

Areas of expertise

Drug development, R&D, regulatory approval and commercialisation

Current external roles

President and Chief Executive Officer of PlaqueTec Limited. Non-Executive Director of Ardelyx Inc, Iox Therapeutics Limited, Oncimmune Holdings plc, Thrombolytic Science International, PhESi LLC and AVROBIO Inc. Chair of Vium Inc, Cocoon Biotech Inc and Cell Medica Limited. Committee member of the U.S. Food & Drug Administration Science Board.

Dr. David Horn Solomon

Chief Executive Officer

David is an experienced public company biotech CEO, board member and biotech investor. He was the CEO of Zealand Pharma A/S (NASDAQ:ZEAL) from 2008 to 2015. Under David’s leadership the company went public on NASDAQ OMX and its lead product, Adlixin®, a GLP-1 receptor agonist for the treatment of type II diabetes, was approved in the US and globally and is now marketed by Sanofi as a monotherapy and in combination with Lantus as Soliqua®. David was also the CEO of Bionor Pharma ASA (OSL:BIONOR) and Akari Therapeutics, Plc (NASDAQ:AKTX), and was the Managing Partner of Sund Capital, ApS, a Nordic healthcare investment fund.

He has earlier served as a faculty member at Columbia University’s College of Physicians and Surgeons in New York City. From 2003 to 2006, David headed healthcare investment at Carrot Capital Healthcare Ventures in New York. David is currently a member of the Board of Directors of TxCell SA (NYSE EURONEXT:TXCL), and was earlier a member of the Boards at Onxeo SA (NYSE EURONEXT:ONXEO) and Promosome, LLC. Dr Solomon studied at Weil Cornell Medicine of Cornell University and its Graduate School of Medical Science where he received his Ph.D.

DHS photo.jpeg

Appointed

July 2018

Areas of expertise

Biotech corporate finance, pharmaceutical development, business development agreements, biotech governance

Current external roles

Director of TxCell SA

David Ellam

Chief Financial Officer

David was appointed Chief Financial Officer and Company Secretary of Silence in July 2016. David holds a B.A. in English & Philosophy from Birmingham University, and is a qualified chartered accountant.

Prior to joining Silence, David’s relevant Biotech experience includes several senior finance roles within both UK and US publicly owned life science companies, most recently as Senior EUMEA Finance Director for BioMarin Pharmaceuticals Inc. from 2010 to 2016. Prior to that he was CFO at Plethora Solutions plc (2008-2009), and Group Financial Controller at Ark Therapeutics from 2001 to 2008, during which time Ark undertook an IPO on the London Stock Exchange.

DavidEllam_160sq_circle.png

Appointed

July 2016

Areas of expertise

Finance, applied to the biotechnology industry.

Current external roles

None

Alistair Gray

Non-Executive Director

Alistair brings a wealth of strategic consultancy and business experience. Having trained as an accountant, his early career was in senior management positions with Unilever and John Wood Group PLC. Alistair was a Director of Arthur Young (now Ernst and Young) Management Consultants and PA Consulting Group for over ten years. Alistair previously chaired the Audit and Remuneration committees of AorTech International PLC and Highland Distillers PLC, as well as the Pension Trustee Board. Alistair also served as a Fellow of the Institute of Directors and Institute of Consultants. His key role at Silence is to chair the Audit and Risk Committee.

AlistairGrey_160sq_circle.png

Appointed

November 2015

Areas of expertise

Strategy, management consulting.

Current external roles

Non-Executive Director with other organisations, serving on the board of one and chairing three Pension Trustee Boards.

Dave Lemus

Non-Executive Director

Dave has over 20 years of US and international business experience in the pharmaceutical and biotechnology industries, having served in executive management and non-executive board roles in multiple US and European private and publicly-traded companies. Dave is currently Executive Vice Chair, Chief Operating Officer and Chief Financial Officer of Proteros biostructures GmbH. Prior to that he served as Interim Chief Financial Officer and Chief Operating Officer of Medigene AG, a publicly-listed German biotechnology company focused on the research and development of T-Cell-Receptor based immunotherapies, and prior to this as Chief Executive Officer of Sigma Tau Pharmaceuticals, Inc. Dave was Chief Financial Officer and Executive VP of MorphoSys AG, taking the Company public in 1999 in Germany's first biotech IPO and held various positions at leading pharma companies including at Hoffman La Roche.

Photo DLemus.jpg

Appointed

June 2018

Areas of expertise

Drug commercialisation, strategic partnerships, financing & transactions

Current external roles

CFO and COO Executive Vice Chair at Proteros Biostructures GmbH, Non-Executive Director of Sorrento Therapeutics Inc., Non-Executive Director of Bioheath Innovation Inc., and Trustee of MIT Club of Washington DC

Dr. Stephen Parker

Non-Executive Director

Dr. Parker served as Non-Executive Chairman from September 2015 to October 2017, having first joined the Board in November 2013. He brings substantial Board experience, with over thirty years’ experience in the healthcare sector. Stephen was previously a Partner with the Celtic Pharma funds, Chief Financial Officer of Oxford GlycoSciences plc and a senior investment banker with Barings, Warburg’s and Apax Partners.

StephenParker_160sq_circle.png

Appointed

September 2015

Areas of expertise

Healthcare, finance, investment banking.

Current external roles

Chairman of Sareum Holdings plc and Non-Executive Director of GammaDelta Limited and Sp2 Consulting Limited

Dr. Andy Richards CBE

Non-Executive Director

Dr. Richards has an established track record in founding and scaling up innovative Biotech and Healthtech companies in the UK. His early career spanned positions with ICI (now AstraZeneca) and PA Technology, and he was a founder and executive director of Chiroscience plc. Since 1999 he has founded, invested in and helped to scale more than 25 innovative ventures including companies such as Vectura, Arakis, Cambridge Biotechnology Ltd and Geneservice. Andy is also a founder member of the Cambridge Angels and a trustee of the British Science Association.

AndyRichards_160sq_circle.png

Appointed

October 2014

Areas of expertise

Business building, venture investment, biotechnology.

Current external roles

Director of Ieso Digital Health, Cancer Research Technology, Sensiia Ltd, and Cambridge University Hospitals NHS Foundation Trust. He is also Chairman of Arecor, Congenica, Abcodia, and the Babraham Research Campus, and an advisor to Cambridge Innovation Capital and the UCL Technology Fund.